Amgen Inc. can now promote the ability of the company’s potent but expensive cholesterol drug to reduce the risk of heart attacks and strokes.

A new drug in early development cuts cholesterol as much as two potent injections recently cleared for sale but lasts much longer, meaning it may need to be given only every three to six months, initial findings suggest. Results with Alnylam Pharmaceuticals and Medicines Co’s experimental product ALN-PCSsc highlight the competition for a market tipped […]